Open Actively Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

About

Brief Summary

The purpose of this study is to:

  • Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
  • Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting
  • Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Observational

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
N/A

Inclusion Criteria:

  • Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
  • Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

  • Current enrollment in a clinical trial for any investigational agent

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Pre-Screen Now
Call Me Back
855-731-6040
Study Stats
Protocol No.
24-6257
Category
Genetic and Rare Diseases
Principal Investigator
Anasheh Halabi, MD, PhD
Anasheh Halabi, MD, PhD
Neuromuscular Medicine, Neurology
Contact
  • Dillan Hayward
Location
  • UCLA Westwood
For Providers
NCT No.
NCT04561518
For detailed technical eligibility, visit ClinicalTrials.gov.